

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 05-Nov-2021
 Document Type: USP Monographs
 DocId: GUID-FAEAB75-A035-4B3A-A071-7791DA815587_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M15560_03_01
 DOI Ref: 36pxk

© 2025 USPC
 Do not distribute

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click

<https://www.uspnf.com/rb-chlordiazepoxide-hcl-clidinium-br-caps-20211104>.

DEFINITION

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules contain NLT 90.0% and NMT 110.0% of the labeled amounts of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) and clidinium bromide ($C_{22}H_{26}BrNO_3$).

IDENTIFICATION

- **A.** The retention times of the major peaks of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

[NOTE—Use low-actinic glassware.]

Buffer: Dissolve 1.92 g of [sodium 1-pentanesulfonate](#) in 900 mL of [water](#) in a 1-L volumetric flask. Adjust with 1 N [sulfuric acid](#) to a pH of 3.8 \pm 0.1. Dilute with [water](#) to volume.

Mobile phase: [Methanol](#), [tetrahydrofuran](#), and *Buffer* (6:24:70)

Diluent: [Methanol](#) and [water](#) (1:1)

Standard solution: 0.1 mg/mL of [USP Chlordiazepoxide Hydrochloride RS](#) and 0.05 mg/mL of [USP Clidinium Bromide RS](#) in *Diluent*

Sample solution: Weigh the contents of NLT 20 Capsules, and calculate the average weight per Capsule. Mix the combined contents of the Capsules, and transfer an amount equivalent to about 5 mg of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) to a 50-mL volumetric flask. Add about 25 mL of *Diluent*, sonicate for 5 min, and shake by mechanical means for 10 min. Dilute with *Diluent* to volume, and filter, discarding the first 20 mL of the filtrate.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 212 nm

Column: 8-mm \times 10-cm; packing [L1](#)

Flow rate: 3 mL/min

Injection size: 20 μ L

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for clidinium bromide and chlordiazepoxide hydrochloride are about 0.5 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 5.0 between the clidinium bromide and chlordiazepoxide hydrochloride peaks

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of chlordiazepoxide hydrochloride from the *Sample solution*

r_S = peak response of chlordiazepoxide hydrochloride from the *Standard solution*

C_S = concentration of [USP Chlordiazepoxide Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of chlordiazepoxide hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of the labeled amount of clidinium bromide ($C_{22}H_{26}BrNO_3$) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of clidinium bromide from the *Sample solution*

r_S = peak response of clidinium bromide from the *Standard solution*

C_S = concentration of [USP Clidinium Bromide RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of clidinium bromide in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

- [DISSOLUTION](#)  (RB-5-Nov-2021) [\(711\)](#).

▲ **Test 1:** Use [Dissolution \(711\), Procedure, Apparatus 1 and Apparatus 2, Immediate-release dosage forms, Procedure for a pooled sample for immediate-release dosage forms](#). ▲ (RB 5-Nov-2021)

Medium: [Water](#); 900 mL

Apparatus 1: 100 rpm

Time: 30 min

Buffer: Dissolve 1.92 g of [sodium 1-pentanesulfonate](#) in 900 mL of [water](#) in a 1-L volumetric flask. Adjust with [dilute sulfuric acid](#) to a pH of 3.8 ± 0.1 . Dilute with [water](#) to volume.

Mobile phase: [Methanol](#), [tetrahydrofuran](#), and *Buffer* (6:18:75)

Standard solution: Prepare a solution having known concentrations of [USP Chlordiazepoxide Hydrochloride RS](#) and [USP Clidinium Bromide RS](#) in *Medium*.

Sample solution: Pass a portion of the solution under test through a suitable filter. Combine equal volumes of the filtered solutions and use the pooled sample for the analysis. Dilute with *Medium* to a concentration that is similar to that of the *Standard solution*, if necessary.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 212 nm

Column: 4-mm × 25-cm; packing [L1](#)

Flow rate: 2 mL/min

Injection size: 100 µL

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for clidinium bromide and chlordiazepoxide hydrochloride are about 0.6 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 5.0 between the clidinium bromide and chlordiazepoxide hydrochloride peaks

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the average percentage of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) or clidinium bromide ($C_{22}H_{26}BrNO_3$) dissolved:

$$\text{Result} = (r_U/r_S) \times (C_S/L) \times V \times 100$$

r_U = peak response of chlordiazepoxide hydrochloride or clidinium bromide from the *Sample solution*

r_S = peak response of chlordiazepoxide hydrochloride or clidinium bromide from the *Standard solution*

C_S = concentration of [USP Chlordiazepoxide Hydrochloride RS](#) or [USP Clidinium Bromide RS](#) in the *Standard solution* (mg/mL)

L = chlordiazepoxide hydrochloride or clidinium bromide label claim (mg)

V = volume of *Medium* (mL), 900

Tolerances: NLT 75% (Q) each of the labeled amounts of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) and clidinium bromide ($C_{22}H_{26}BrNO_3$) are dissolved.

▲ **Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

Protect the *Standard stock solution*, *Standard solution*, and *Sample solution* from light.

Medium: 0.1 N [hydrochloric acid](#); 500 mL

Apparatus 1: 100 rpm

Time: 30 min

Buffer: Transfer 1.36 g of [monobasic potassium phosphate](#) to 1000 mL of [water](#). Add 1.0 mL of [triethylamine](#) and adjust with 25% phosphoric acid to a pH of 3.6.

Mobile phase: [Acetonitrile](#), [methanol](#), and *Buffer* (25:10:65)

Standard stock solution: 0.32 mg/mL of [USP Chlordiazepoxide Hydrochloride RS](#) and 0.16 mg/mL of [USP Clidinium Bromide RS](#) in [methanol](#). Sonicate to dissolve.

Standard solution: 0.01 mg/mL of [USP Chlordiazepoxide Hydrochloride RS](#) and 0.005 mg/mL of [USP Clidinium Bromide RS](#) from the *Standard stock solution*, in *Medium*. Store at 5°.

Sample solution: Pass a portion of the solution under test through a suitable PVDF filter of 0.45-µm pore size, discarding the first 5 mL of filtrate. Store at 5°.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 212 nm

Column: 4.6-mm × 15-cm; 4.0-µm packing [L1](#)

Temperatures

Autosampler: 5°

Column: 50°

Flow rate: 1 mL/min

Injection volume: 25 µL

Run time: NLT 2 times the retention time of chlordiazepoxide

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for clidinium and chlordiazepoxide are about 0.43 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 5.0 between clidinium and chlordiazepoxide

Tailing factor: NMT 2.0 for clidinium and chlordiazepoxide

Relative standard deviation: NMT 2.0% for clidinium and chlordiazepoxide

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) and clidinium bromide ($C_{22}H_{26}BrNO_3$) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

r_U = peak response of chlordiazepoxide or clidinium from the *Sample solution*

r_S = peak response of chlordiazepoxide or clidinium from the *Standard solution*

C_S = concentration of [USP Chlordiazepoxide Hydrochloride RS](#) or [USP Clidinium Bromide RS](#) in the *Standard solution* (mg/mL)

V = volume of *Medium*, 500 mL

L = label claim for chlordiazepoxide hydrochloride or clidinium bromide (mg/Capsule)

Tolerances: NLT 80% (Q) each of the labeled amount of chlordiazepoxide hydrochloride ($C_{16}H_{14}ClN_3O \cdot HCl$) and clidinium bromide ($C_{22}H_{26}BrNO_3$) is dissolved. ▲ (RB 5-Nov-2021)

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES

- LIMIT OF CHLORDIAZEPOXIDE RELATED COMPOUND A AND 2-AMINO-5-CHLOROBENZOPHENONE

Standard solution A: 1 mg/mL of [USP Chlordiazepoxide Related Compound A RS](#) in [acetone](#)

Standard solution B: 50 µg/mL of [USP 2-Amino-5-chlorobenzophenone RS](#) in [acetone](#)

Sample solution: Transfer an amount equivalent to 25 mg of chlordiazepoxide hydrochloride from Capsule contents to a 10-mL conical flask, add 2.5 mL of [acetone](#), and shake. Allow any undissolved particles to settle, and use the supernatant.

Chromatographic system

(See [Chromatography \(621\), General Procedures, Thin-Layer Chromatography](#).)

Adsorbent: 0.25-mm layer of [chromatographic silica gel](#)

Application volume: 50 µL for the *Sample solution*, 15 µL for *Standard solution A*, and 10 µL for *Standard solution B*

Developing solvent system: [Ethyl acetate](#)

Spray reagent: [2 N sulfuric acid](#)

Analysis

Samples: *Standard solutions* and *Sample solution*

Proceed as directed in the chapter. Develop the chromatogram in a chromatographic chamber (not previously saturated with the developing solvent) in the *Developing solvent system* until the solvent front has moved three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by lightly spraying with

Spray reagent. Dry at 105° for 15 min, and then spray in succession with [sodium nitrite](#) solution (1 in 1000), [ammonium sulfamate](#) solution (1 in 200), and [N-\(1-naphthyl\)ethylenediamine dihydrochloride](#) solution (1 in 1000).

Acceptance criteria: Any spots from the *Sample solution* are not greater in size or intensity than the spots at the respective R_f values produced by the *Standard solutions*, corresponding to NMT 3.0% of chlordiazepoxide related compound A and to NMT 0.1% of 2-amino-5-chlorobenzophenone.

• **LIMIT OF CLIDINIUM BROMIDE RELATED COMPOUND A**

Extracting solvent mixture: [Dehydrated alcohol](#) and [cyclohexane](#) (1:1)

Identification solution: Dissolve 50 mg of [USP Clidinium Bromide RS](#) in 1 mL of 0.1 N methanolic hydrochloric acid. To this solution add 20 µL of a solution of 25 mg/mL of [USP Clidinium Bromide Related Compound A RS](#) in [methanol](#). Prepare this solution at the time of use.

Standard solution: 50 mg/mL of [USP Clidinium Bromide RS](#) in 0.1 N methanolic hydrochloric acid. [NOTE—Prepare this solution at the time of use.]

Sample solution: Empty a number of Capsules, equivalent to 25 mg of clidinium bromide, into a glass-stoppered centrifuge tube, and add 5 mL of the *Extracting solvent mixture*. Heat the tube gently, with shaking, to 50°, centrifuge, and decant the clear supernatant into a second tube. Repeat the addition of *Extracting solvent mixture* twice, heating, centrifuging, and decanting as before, and combine the three extracts in a single tube. Gently heating, evaporate the combined extracts under a stream of nitrogen to dryness. Dissolve the residue in 0.5 mL of [methanol](#).

Chromatographic system

(See [Chromatography \(621\), General Procedures, Thin-Layer Chromatography](#).)

Adsorbent: 0.25-mm layer of chromatographic silica gel mixture

Application volume: 20 µL

Developing solvent system: [Acetone](#), [methanol](#), [water](#), and [hydrochloric acid](#) (70:20:5:5)

Spray reagent: Dissolve 850 mg of [bismuth subnitrate](#) in a mixture of 10 mL of [glacial acetic acid](#) and 40 mL of [water](#). In a separate container, dissolve 20 g of [potassium iodide](#) in 50 mL of [water](#). Mix the two solutions, and dilute with dilute [sulfuric acid](#) (1 in 10) to 500 mL. Add 7.5 ± 2.5 g of [iodine](#), and mix until solution is complete.

Chromatographic plates: Predevelop suitable thin-layer chromatographic plates by placing in a chromatographic chamber saturated with *Developing solvent system*, and allow the *Developing solvent system* to move 15 cm. Remove the plates from the chamber, dry at 105° for 15 min, and cool.

Analysis

Samples: *Identification solution*, *Standard solution*, and *Sample solution*

Proceed as directed in the chapter. Place the plates in an unsaturated chromatographic chamber containing freshly prepared *Developing solvent system*, and develop the chromatogram until the solvent front has moved 15 cm. Remove the plates, and dry at 105° for 10 min. Cool to room temperature, and spray with *Spray reagent*. Any spot in the chromatogram of the *Sample solution* occurring at an R_f value of 0.4 is not greater in size or intensity than the corresponding spot in the chromatogram of the *Identification solution*; and the *Standard solution* shows no spot at the R_f value corresponding to that of clidinium bromide related compound A.

Acceptance criteria: NMT 1.0% of clidinium bromide related compound A

ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.

Add the following:

▲• **LABELING:** When more than one *Dissolution* test is used, the labeling states the *Dissolution* test used only if *Test 1* is not used. ▲ (RB 5-Nov-2021)

• **USP REFERENCE STANDARDS (11).**

[USP 2-Amino-5-chlorobenzophenone RS](#)

2-Amino-5-chlorobenzophenone.

$C_{13}H_{10}ClNO$ 231.68

[USP Chlordiazepoxide Hydrochloride RS](#)

[USP Chlordiazepoxide Related Compound A RS](#)

7-Chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one 4-oxide.

$C_{15}H_{11}ClN_2O_2$ 286.72

[USP Clidinium Bromide RS](#)

[USP Clidinium Bromide Related Compound A RS](#)

3-Hydroxy-1-methylquinuclidinium bromide.

$C_8H_{16}BrNO$ 222.13

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE CAPSULES	Documentary Standards Support	SM42020 Small Molecules 4

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 30(1)

Current DocID: GUID-FAEAB75-A035-4B3A-A071-7791DA815587_3_en-US

DOI: https://doi.org/10.31003/USPNF_M15560_03_01

DOI ref: [36pxk](#)

OFFICIAL